New drug reduces cardiovascular events in patients with type 2 diabetes

Albiglutide – a glucagon-like peptide 1 receptor agonist -results in fewer cardiovascular events in people with type 2 diabetes and existing cardiovascular disease than treatment with placebo, according to new research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) and published in The Lancet  The GSK sponsored Harmony-Outcomes study was led by Professor Stefano Del Prato, Department of Clinical & Experimental Medicine, University of Pisa, Italy and Professor John McMurray, British Heart Foundation Cardiovascular Research Centre, University of Glasgow, UK. This randomised, double-blind, placebo-controlled, event-driven trial took place at 610 sites in 28 countries. Patients with